Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia
Christopher Allen, Robert K. Hills, Katarina Lamb, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1891-1901
Closed Access | Times Cited: 137

Showing 26-50 of 137 citing articles:

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
Raphaël Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood (2018) Vol. 132, Iss. 2, pp. 187-196
Open Access | Times Cited: 59
Clinical implications of molecular markers in acute myeloid leukemia
Sabine Käyser, Mark J. Levis
European Journal Of Haematology (2018) Vol. 102, Iss. 1, pp. 20-35
Open Access | Times Cited: 59
Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Wenlan Chen, Hui Xie, Hongxiang Wang, et al.
PLoS ONE (2016) Vol. 11, Iss. 1, pp. e0146614-e0146614
Open Access | Times Cited: 57
Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐up
Federico Mosna, Cristina Papayannidis, Giovanni Martinelli, et al.
American Journal of Hematology (2015) Vol. 90, Iss. 6, pp. 515-523
Open Access | Times Cited: 55
Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AML
Sewa Rijal, Shaun Fleming, Nik Cummings, et al.
Blood (2015) Vol. 125, Iss. 18, pp. 2815-2824
Open Access | Times Cited: 51
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Katherine Tarlock, Todd A. Alonzo, Yi-Cheng Wang, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 16, pp. 5038-5048
Open Access | Times Cited: 49
Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?
Daniela Cilloni, Jessica Petiti, Valentina Rosso, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 9, pp. 2249-2249
Open Access | Times Cited: 48
Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations
Elena Manara, Valéria Bisio, Riccardo Masetti, et al.
Leukemia (2013) Vol. 28, Iss. 5, pp. 1132-1134
Open Access | Times Cited: 46
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome
Chae‐Yin Cher, GM Leung, Chun Hang Au, et al.
Blood Cancer Journal (2016) Vol. 6, Iss. 7, pp. e442-e442
Open Access | Times Cited: 39
Acute Myeloid Leukemia Genetics: Risk Stratification and Implications for Therapy
Michael Wang, Nathanael G. Bailey
Archives of Pathology & Laboratory Medicine (2015) Vol. 139, Iss. 10, pp. 1215-1223
Open Access | Times Cited: 40
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
Nicolas Boissel, Aline Renneville, Thibaut Leguay, et al.
Haematologica (2015) Vol. 100, Iss. 6, pp. 780-785
Open Access | Times Cited: 40
Minimal residual disease–directed therapy in acute myeloid leukemia
Sabine Käyser, Richard F. Schlenk, David Grimwade, et al.
Blood (2015) Vol. 125, Iss. 15, pp. 2331-2335
Open Access | Times Cited: 39
Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia
Celalettin Üstün, Guido Marcucci
Current Opinion in Hematology (2015) Vol. 22, Iss. 2, pp. 85-91
Closed Access | Times Cited: 37
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling
Katherine Tarlock, Shan Zhong, Yuting He, et al.
Oncotarget (2018) Vol. 9, Iss. 41, pp. 26417-26430
Open Access | Times Cited: 33
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
Seiichiro Katagiri, SungGi Chi, Yosuke Minami, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4694-4694
Open Access | Times Cited: 18
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
Daisuke Ikeda, SungGi Chi, Satoshi Uchiyama, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 11, pp. 5950-5950
Open Access | Times Cited: 18
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients
Gautam Borthakur, Farhad Ravandi, Keyur P. Patel, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 11, pp. 1427-1434
Closed Access | Times Cited: 17
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights
Mona S. Abdellateif, Ahmed Bayoumi, Mohammed Mohammed
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 785-799
Open Access | Times Cited: 10
The prospective use of avapritinib in relapsed/refractory (R/R) RUNX1-RUNX1T1-positive AML patients with KIT mutation
Shuhong Han, Xiao-Yan Xu, Meng Zhou, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial
Mayu Tokumasu, Chisato Murata, Akira Shimada, et al.
Leukemia (2015) Vol. 29, Iss. 12, pp. 2438-2441
Closed Access | Times Cited: 32
Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
Sabine Käyser, Roland B. Walter, Wendy Stock, et al.
Current Hematologic Malignancy Reports (2015) Vol. 10, Iss. 2, pp. 132-144
Closed Access | Times Cited: 32
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors
Nicolas Duployez, Christophe Willekens, Alice Marceau‐Renaut, et al.
Expert Review of Hematology (2014) Vol. 8, Iss. 1, pp. 43-56
Closed Access | Times Cited: 31
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
Sabine Käyser, Michael Krämer, David Martínez‐Cuadrón, et al.
Haematologica (2021) Vol. 107, Iss. 4, pp. 836-843
Open Access | Times Cited: 22
What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
Susan DeWolf, Martin S. Tallman, Jacob M. Rowe, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 29, pp. 4693-4703
Closed Access | Times Cited: 8
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia
Bruno C. Medeiros, Megan Othus, Min Fang, et al.
Haematologica (2014) Vol. 100, Iss. 3, pp. 331-335
Open Access | Times Cited: 25

Scroll to top